0001562180-20-004359.txt : 20200609
0001562180-20-004359.hdr.sgml : 20200609
20200609161745
ACCESSION NUMBER: 0001562180-20-004359
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200605
FILED AS OF DATE: 20200609
DATE AS OF CHANGE: 20200609
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GILMAN STEVEN C
CENTRAL INDEX KEY: 0001379970
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36352
FILM NUMBER: 20952024
MAIL ADDRESS:
STREET 1: 110 HARTWELL AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Akebia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001517022
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208756903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-871-2098
MAIL ADDRESS:
STREET 1: 245 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2020-06-05
false
0001517022
Akebia Therapeutics, Inc.
AKBA
0001379970
GILMAN STEVEN C
C/O AKEBIA THERAPEUTICS, INC.
245 FIRST ST.
CAMBRIDGE
MA
02142
true
false
false
false
Common Stock
2020-06-05
4
A
false
13700.00
0.00
A
43431.00
D
Common Stock
2020-06-08
4
S
false
4567.00
12.08
D
38864.00
D
Stock Option (Right to buy)
11.96
2020-06-05
4
A
false
20100.00
0.00
A
2021-06-05
2030-06-05
Common Stock
20100.00
20100.00
D
The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019.
Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
/s/ Nicole R. Hadas, attorney-in-fact for Steven C. Gilman
2020-06-09